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Background: Several clinical trials have assessed the 
protective potential of chloroquine and hydroxychloro-
quine. Chronic exposure to such drugs might lower the 
risk of infection with severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) or severe coronavirus dis-
ease (COVID-19). Aim: To assess COVID-19 incidence 
and risk of hospitalisation in a cohort of patients 
chronically taking chloroquine/hydroxychloroquine. 
Methods: We used linked health administration data-
bases to follow a cohort of patients with chronic pre-
scription of hydroxychloroquine/chloroquine and a 
control cohort matched by age, sex and primary care 
service area, between 1 January and 30 April 2020. 
COVID-19 cases were identified using International 
Classification of Diseases 10 codes. Results: We ana-
lysed a cohort of 6,746 patients (80% female) with 
active prescriptions for hydroxychloroquine/chloro-
quine, and 13,492 controls. During follow-up, there 
were 97 (1.4%) COVID-19 cases in the exposed cohort 
and 183 (1.4%) among controls. The incidence rate was 
very similar between the two groups (12.05 vs 11.35 
cases/100,000 person-days). The exposed cohort was 
not at lower risk of infection compared with controls 
(hazard ratio (HR): 1.08; 95% confidence interval (CI): 
0.83–1.44; p = 0.50). Forty cases (0.6%) were admit-
ted to hospital in the exposed cohort and 50 (0.4%) in 
the control cohort, suggesting a higher hospitalisation 
rate in the former, though differences were not con-
firmed after adjustment (HR: 1·46; 95% CI: 0.91–2.34; 
p = 0.10). Conclusions: Patients chronically exposed to 
chloroquine/hydroxychloroquine did not differ in risk 
of COVID-19 nor hospitalisation, compared with con-
trols. As controls were mainly female, findings might 
not be generalisable to a male population.
Introduction
The coronavirus disease (COVID-19) outbreak that 
started in January in China evolved into a pandemic 
with global cumulative numbers totalling 110.7 mil-
lion confirmed cases and over 2.4 million deaths by 23 
February 2021, with figures constantly increasing [1].
Since the beginning of the pandemic, non-pharmaceu-
tical interventions such as physical distancing, lock-
downs and the use of face masks in public spaces have 
been implemented in an effort to reduce transmission 
of SARS-CoV-2. However, such strict non-pharmaceuti-
cal interventions can only be maintained for a limited 
time without critically affecting citizens’ psychological 
health and the economy.
Prophylactic pharmaceutical interventions for COVID-
19 have been explored and developed since the out-
set of the pandemic. Early clinical reports from China 
and France suggested the potential antiviral activity 
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of 4-aminoquinolines (chloroquine (CQ) and its ana-
logue, hydroxychloroquine (HCQ)) against COVID-19 
[2,3]. Supported by preclinical evidence of its activity 
in cell culture [4], both testing and empirically using 
these drugs in the prevention and treatment of COVID-
19 increased [5]. However, a retrospective cohort study 
reported in July 2020 that continuous HCQ therapy 
does not prevent infection with SARS-CoV-2, based on 
a large healthcare database analysis in Israel [6].
CQ is one of the most frequently prescribed drugs in 
the world and has been used for treating malaria and 
as chemoprophylaxis in travellers for decades, even 
for long periods of exposure [7]. Its safety profile is 
well known and its risk-benefit is deemed favourable 
to treat and prevent malaria [8]. HCQ, a chloroquine 
hydroxylated derivate, has also been widely used. 
Data from observational studies suggest that HCQ is 
threefold less toxic than CQ; therefore, while the type 
of adverse events is similar for both drugs, they occur 
less frequently with HCQ [9]. Moreover, CQ and HCQ 
are known immunomodulators that have been used for 
decades as chronic treatments in certain rheumatolog-
ical diseases [10-12].
Based on this background, several clinical trials were 
designed to assess the protective potential of 4-amino-
quinolines (CQ or HCQ) against SARS-CoV-2 infection, 
given as pre-exposure and post-exposure prophylaxis 
in highly exposed populations, such as healthcare pro-
fessionals (clinicaltrials.gov register: NCT04303507, 
NCT04308668, NCT04304053).
During the first wave of the pandemic it was therefore 
reasonable to consider whether people who are chroni-
cally taking CQ or HCQ for any therapeutic indication 
may have less risk of SARS-CoV-2 infection and, if they 
contract COVID-19, whether they develop less severe 
disease.
For this reason, we have compared the incidence of 
COVID-19 in people who are chronic users of CQ or 
HCQ and those who are not, among people living in 
Catalonia, Spain.
Methods
Catalonia is an autonomous province in the west of 
Spain that has universal public healthcare coverage, 
including primary and hospital healthcare, as well as 
prescription drug costs. Integrated registries are used 
to manage administrative and clinical information on 
the entire population in Catalonia, i.e. 7.5 million peo-
ple, including invoicing systems for pharmacies, epi-
sode diagnoses for budgeting and payment purposes, 
clinical information exchange systems across health-
care providers and dedicated registries for epidemio-
logical surveillance.
We report this study according to the guidelines for 
observational studies using routinely collected data.
Registry features and data acquisition
A Catalan central registry of insured persons allows 
linking of information at the individual level between 
all health administration databases, and includes 
individual sociodemographic data and aggregated 
primary care service area data. An individual’s health-
care identification code allows Catalan residents to 
be tracked across several health administration data-
bases, including the acute and emergency hospitals 
and emergency discharge datasets, conjunt mínim 
bàsic de dades d’hospitalitzats d’aguts (CMBD-HA) 
and conjunt mínim bàsic de dades d’urgències hos-
pitalàries (CMBD-URG); the pharmacy invoicing data-
base; the episode diagnosis database for primary care, 
conjunt mínim de dades d’atenció primària (CMBD-AP), 
which records information on comorbidity and date of 
diagnosis; the laboratory database, including data of 
SARS-CoV-2 nucleic acid amplification test results; and 
the specific epidemiological mandatory registry for 
SARS-CoV-2 infection. All CMBD databases register the 
information using the Ninth and Tenth Revisions of the 
International Classification of Diseases codes (ICD-9 
and ICD-10) [13,14], and the pharmacy invoicing data-
base uses Anatomical Therapeutic Chemical/Defined 
Daily Dose index codes established by the World Health 
Organization Collaborating Centre in Oslo, Norway. The 
registries have an automated data validation system 
to check consistency of data and identify potential 
errors, and external audits are performed periodically 
to ensure quality and reliability of data.
Box 1
  ICD-9 codes used for baseline comorbidities, Catalonia, 
Spain, 2020
Asthma: 493xx
Chronic obstructive pulmonary disease: 491.0, 419.2x, 
491.8, 491.9, 492xx, 494x, 496
Chronic renal failure: 403.01, 403.11, 403.91, 585xx, 
586xx, 588.0
Congestive heart failure: 398.91, 402.01, 402.11, 402.91, 
404.01, 404.03, 404.11, 404.13, 404.91, 404.93,428xx
Diabetes mellitus: 250xx
Dementia: 290xx, 331.0, 331.1, 331.2
Hypertension: 401x, 402xx, 403xx, 404xx, 405xx
Ischaemic heart disease: 410xx, 411xx, 412, 413xx, 414xx
Liver cirrhosis: 571.2, 571.5
Malignant neoplasm: 140xx-230xx
Stroke: 430, 431,432x, 433xx, 434xx, 436, 437, 437.0, 
437.1,437.8, 437.9, 438xx














     (N = 20,238)      p value
n % n      %      N      %
Age (years)
Mean (SD) 57.1 (15.8) – 57.1 (15.8) –      57.1 (15.8) –
     1.000Median (Q1, Q3) 57.0 (45.0, 69.0) – 57.0 (45.0, 69.0) –   57.0 (45.0, 69.0) –
Min–Max 8.0–96.0 – 8.0–96.0 –       8.0–96.0 –
Sex
Female 11,366 84.2 5,683    84.2    17,049    84.2
   1.000
Male 2,126 15.8 1,063 15.8 3,189 15.8
Comorbidities
Hypertension 4,056 30.3 2,513 37.3 6,569 32.7 < 0.001
Diabetes 1,512 11.2 763 11.3 2,275 11.3 0.841
Congestive heart failure 494 3.7 415 6.2 909 4.5 < 0.001
COPD 896 6.7 829 12.3 1,725 8.5 < 0.001
Chronic renal disease 798 5.9 851 12.6 1,649 8.2 < 0.001
Asthma 954 7.1 633 9.4 1,587 7.9 < 0.001
Dementia 227 1.7 78 1.2 305 1.5 0.004
Liver cirrhosis 63 0.5 60 0.9 123 0.6 < 0.001
Stroke 629 4.7 444 6.6 1,073 5.3 < 0.001
Coronary artery disease 517 3.8 409 6.1 926 4.6 < 0.001
Cancer 1,530 11.4 880 13.1 2,410 11.9 < 0.001
Tobacco use
  Non-smoker 5,319 58.7 2,756     56.1     8,075     57.8
    < 0.001  Current smoker 2,310 25.5 1,238 25.2     3,548     25.4
  Former smoker 1,440 15.9 919 18.7     2,359     16.9
AMG
  Very low risk 8,238 61.2 1,817 27.0    10,055    49.8
   < 0.001
  Low risk 3,352 24.9 2,753 40.9     6,105     30.2
  Moderate risk 1,442 10.7 1,581 23.5     3023     15.0
  High risk 339 2.5 467 6.9      806      4.0
  Very high risk 82 0.6 114 1.7      196      1.0
IS level
  Exempts 540 4.0 325 4.8      865      4.3
     < 0.0012
  < 18,000 € 8,056 59.7 4,170 61.8    12,226    60.4
  18,001–100,000 € 4,776 35.4 2,193 32.5     6,969     34.4
  > 100,000 € 120 0.9 58 0.9      178      0.9
PCL deprivation index
  0–32.2  3,490 26.3 1,745 26.3     5,235     26.3
    1.000
  32.2–41.2   3,210 24.2 1,605 24.2     4,815     24.2
  41.2–49.7  3,296 24.8 1,648 24.8     4,944     24.8
  49.7–100 3282 24.7 1,641 24.7     4,923     24.7
CQ/HCQ 0 0 6,746 100.0 6,746 33.3
< 0.001CQ 0 0 114 1.7 114 1.7
HCQ 0 0 6,648 98.5 6,648 98.5
Hospitalisation 50 0.4 40 0.6 90 0.4 0.025
COVID-19 diagnosis 183 1.4 97 1.4 280 1.4 0.640
AMG: Adjusted Morbidity Groups; COPD: chronic obstructive pulmonary disease; COVID-19: coronavirus disease; CQ: chloroquine; HQ: 
hydroxychloroquine; IS level: individual socioeconomic level; PCL deprivation index: index of deprivation at primary care service area level; 
Q1: first quartile; Q3: third quartile; SD: standard deviation.
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Study design and participants
We conducted a population-based, prospective cohort 
study using linked health administration databases in 
Catalonia, Spain. The first Catalan case in the COVID-19 
outbreak was reported in late February, lockdown was 
declared on 13 March and peak incidence was reached 
in early April, with a progressive decline in incidence 
thereafter. Thus, we studied the period between 1 
January and 30 April 2020.
The exposed cohort included patients who, on 1 
January 2020, had been dispensed CQ/HCQ treatment 
in the last 6 months according to the pharmacy invoic-
ing database. The Catalan central registry of insured 
persons was used to select a control cohort of people 
who, on 1 January 2020, did not have any invoices for 
CQ/HCQ in the same period. For each exposed patient, 
two non-exposed individuals (controls) of the same 
age, sex and primary care service area were chosen.
Information regarding baseline comorbidities was 
obtained from the CMBD-AP using the ICD-9 given 
in Box 1. A comorbidity index was also used (Adjusted 
Morbidity Groups), a recently developed morbid-
ity measurement that enables classification of the 
population into five morbidity groups (very low risk, 
low risk, moderate risk, high risk, very high risk) [15]. 
Information regarding socioeconomic status was also 
retrieved from the Catalan central registry of insured 
persons for every subject using two levels (individual 
and primary care service area). Individual socioeco-
nomic status was derived from the individual yearly 
income range information used to calculate pharmacy 
copayment. Copayment ranges are derived from tax 
declarations and/or social security benefits received, 
as follows: exempted (non-working population or peo-
ple receiving non-contributory pension), < €18,000 
($US 20,468) income per year; €18,000 ($US 20,468) 
to €100,000 ($US 113,710) income per year; and > €100 
000 ($US 113,710) income per year. The primary care 
service area socioeconomic status is defined by the 
index of deprivation that ranges from 0 (less deprived) 
to 100 (more deprived); this was also a control cohort 
matching parameter [16].
Estimation of chronic exposure to chloroquine/
hydroxychloroquine
We considered that patients had chronic exposure to 
CQ/HCQ if—according to the pharmacy invoicing data-
base—they had been dispensed CQ/HCQ (ATC P01BA01 
Figure 1
Cumulative incidence of SARS-CoV-2 infection in the cohort exposed to chloroquine/hydroxychloroquine and the control 
cohort, Catalonia, Spain, 1 January–30 April 2020
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Control: non-exposed control cohort; CQ/HCQ: cohort exposed to chloroquine/hydroxychloroquine; SARS-CoV-2: severe acute respiratory 
syndrome coronavirus 2.
5www.eurosurveillance.org
or P01BA02) at least once in January 2020 and also 
during the previous 6 months or more, with this treat-
ment ongoing during the study period.
Outcome
Our main outcome of interest was incidence of SARS-
CoV-2 infection or COVID-19 diagnosis, as defined 
by one or more of the following: (i) a record with 
ICD-10 codes B97.29 or B34.2, as retrieved from the 
CMBD-HA, CMBD-URG or CMBD-AP datasets; (ii) a 
record of infection retrieved from the specific registry 
for SARS-CoV-2 infection or (iii) a positive SARS-CoV-2 
RT-PCR test in the laboratory database. Patients were 
followed from 1 January 2020 until diagnosis or until 30 
April 2020 (end of follow-up). As a secondary outcome, 
we also retrieved data on admission to hospital due to 
COVID-19.
Statistical analysis
We used descriptive statistics to show the base-
line demographic and comorbidity information of the 
individuals included in our analyses. Incidence rate 
of SARS-CoV-2 infection was calculated for both the 
exposed cohort and the control cohort. The numera-
tor of the incidence was the number of subjects with 
SARS-CoV-2 infection observed during follow-up. The 
denominator, in person-days, was the follow-up dura-
tion, which ended on 30 April 2020, at the time of a 
SARS-CoV-2 infection diagnosis, on the date of death 
or at the last available follow-up.
For the time to event analyses for the main outcome 
(SARS-CoV-2 infection or COVID-19), cumulative inci-
dence of event curves were estimated for each cohort 
(exposed and control), considered separately, using 
the Kaplan-Meier method and compared statistically 
using the log rank test. We fitted a priori multivariable 
Cox proportional hazards regression model adjusted 
for all comorbidities and individual socioeconomic sta-
tus to determine which variables were associated with 
an increased risk of infection.
The same analysis was applied to time to event for 
the secondary outcome (admission to hospital due to 
COVID-19).
We checked the proportional hazards assumption for 
all covariates using graphical methods (inspection of 
log minus log plot of survival).
R statistical software, version R-4.0.0 was used for all 
analyses [17].
Ethical statement
No patients were involved in setting the research ques-
tion or the outcome measures, nor were they involved 
in the design or implementation of the study. Data from 
different health administration databases were linked 
and de-identified by a team not involved in the study 
analysis; only a full de-anonymised database was 
available to the study investigators. The study proto-
col was approved by the Ethical Review Board of Vall 
d’Hebron University Hospital (Code VHI-HCQ-2020–01), 
Barcelona, Spain.
Results
At the start of the follow-up (1 January 2020), 6,746 
patients were identified as chronic users of CQ (114)/
Table 2
Adjusted hazard ratios and 95% confidence intervals for episodes of SARS-CoV-2 infection by comorbidities and individual 
socioeconomic status, Catalonia, Spain, 30 April 2020
Characteristics Adjusted hazard ratio Lower 0.95 CI Upper 0.95 CI p value
Hypertension 0.93 0.68 1.27 0.65
Diabetes 1.17 0.81 1.70 0.40
Heart failure 1.24 0.76 2.04 0.40
COPD 1.59 1.08 2.35 0.01
Chronic renal disease 1.30 0.87 1.95 0.20
Asthma 1.19 0.78 1.82 0.40
Dementia 4.33 2.61 7.17 < 0.001
Liver cirrhosis 0.70 0.10 5.03 0.72
Stroke 1.38 0.88 2.16 0.16
Coronary artery disease 1.27 0.77 2.10 0.35
Cancer 1.05 0.73 1.52 0.79
Current smoker 0.67 0.46 0.93 0.03
Former smoker 1.32 0.95 1.82 0.10
IS level < 18,000 € 1.04 0.55 1.99 0.90
IS level 18,001–100,000 € 0.85 0.44 1.68 0.60
IS level > 100,000 € 0.79 0.10 6.17 0.80
CQ/HCQ exposure 1.08 0.83 1.44 0.50
CI: confidence interval; COPD: chronic obstructive pulmonary disease; CQ/HCQ: chloroquine/hydroxychloroquine; IS level: individual 
socioeconomic level; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.
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HCQ (6,648) and matched to 13,492 controls. All but 
one patient had at least one additional dispensation 
of CQ/HCQ during the study period. Baseline charac-
teristics are described in  Table 1. Median age in both 
cohorts was 57 years (interquartile range: 45–69) and 
84.2% were women. In general, patients in the exposed 
cohort had more comorbidities and lower individual 
socioeconomic status than those in the control cohort.
A total of 97 cases in the exposed cohort (1.4%) and 
183 (1.4%) in the control cohort had SARS-CoV-2 infec-
tion during the follow-up. The incidence rate was simi-
lar between both cohorts (12.05 vs 11.35 cases/100,000 
person-days). No differences were observed in the 
crude cumulative incidence of event (SARS-CoV-2 infec-
tion) curves (Figure 1). 
Table 2 shows hazard ratios (HRs) for time-to-infection 
for the CQ/HCQ cohort after adjusting for comorbidities 
and individual socioeconomic status. Patients 
chronically exposed to CQ/HCQ were not at lower risk 
of infection compared to controls (HR: 1.08; 95% confi-
dence interval (CI): 0.83–1.44; p = 0.50).
Unadjusted estimates for risk of hospitalisation for 
COVID-19 showed that 40 (0.6%) cases were admitted 
to public hospitals in the exposed cohort and 50 (0.4%) 
in the control cohort, with significant differences 
between the two cohorts in the unadjusted cumulative 
incidence of event curves (Figure 2).
Adjusted estimates by comorbidities and socioeco-
nomic status did not show significant differences (HR: 
1.46; 95% CI: 0.91–2.34; p = 0.10). In particular, demen-
tia was associated with a substantial increase of risk 
(Table 3). 
Discussion
After comparing the two cohorts, we found no differ-
ences between the incidence of COVID-19 in those 
under long-term CQ/HCQ therapy and the controls. 
When analysing unadjusted risk of hospitalisation for 
COVID-19, patients receiving 4-aminoquinolines had 
more risk of hospitalisation; however, this effect did 
not persist after adjustment for comorbidities, sug-
gesting that it might be because of the higher propor-
tion of comorbidities among the exposed patients.
The rapid spread of SARS-CoV-2 led to the need to seek 
pharmaceutical prevention strategies while waiting for 
an effective and safe vaccine. Different strategies have 
been evaluated, mainly in high-risk groups such as 
healthcare workers. CQ/HCQ were the first candidates 
to be evaluated, because of evidence shown in experi-
mental models and incipient observational studies. As 
Figure 2
Cumulative incidence of hospitalisation for COVID-19 in cohort exposed to chloroquine/hydroxychloroquine and control 
cohort, Catalonia, Spain, 30 April 2020
+ + +++++ + + + ++ + + + +++++++ ++ +++ ++ ++ + + + + + ++ +
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Control: non-exposed control cohort; COVID-19: coronavirus disease: CQ/HCQ: cohort exposed to chloroquine/hydroxychloroquine.
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at March 2020, more than 80 clinical trials have been 
registered to assess the potential activity of CQ/HCQ 
against COVID-19, including the full spectrum of symp-
toms. Although early observational studies reported 
positive effects, as larger observational studies and 
clinical trials emerged, the evidence to support the use 
of 4-aminoquinolines declined. There are already sev-
eral clinical trials that have failed to demonstrate clini-
cal or virological efficacy of these drugs [18,19], while 
others concluded that their use could even be harmful 
[20,21].
The current evidence from clinical trials refers to the 
use of 4-aminoquinolines as either a treatment of 
established infection or prophylaxys after exposure. 
Results from clinical trials showed that after high-risk 
or moderate-risk exposure to SARS-CoV-2, HCQ did not 
prevent illness compatible with COVID-19 or confirmed 
COVID-19 when used as postexposure prophylaxis 
within 4 days after exposure [22,23].
The observed incidence rate alone is not an appropriate 
measure of the protective efficacy or harmful effects 
of pharmaceutical interventions against SARS-CoV-2, 
since despite comorbidity adjustments, colliding bias 
and residual confounding may persist. Antiviral activ-
ity of either CQ/HCQ could still have a role in reduc-
ing population transmission of SARS-CoV-2 or reducing 
the severity of COVID-19 in individuals before they are 
exposed. This should be studied through randomised, 
prospective comparisons [24]. Therefore, although the 
observed incidence rate in patients exposed to CQ/
HCQ could be the same as in controls, as in our study, 
it would still be reasonable to accept a strategy that 
may reduce the viral load and diminish symptoms and 
severity in infected individuals.
We observed that patients receiving CQ/HCQ had more 
admissions to hospital than controls (0.6% vs 0.4%, 
p = 0.025), but the adjusted estimates by comorbidi-
ties did not show significant differences in the risk 
of hospitalisation (HR: 1.5 95% CI: 0.9–2.3; p = 0.10), 
suggesting that comorbidity burden could explain the 
differences. In particular, although comorbidities were 
considered as covariates to adjust the risk models in 
our analysis, dementia showed a significant asso-
ciation with higher risk of infection. The greatest pro-
portion of patients affected by COVID-19 has been in 
long-term care facilities, with nursing home residents 
accounting for ca 25–50% of documented deaths 
[25,26]. As dementia patients are likely to live in nurs-
ing homes, this association could also be attributed 
to living situation; regardless, we might still consider 
dementia as a surrogate marker.
We did not find individual socioeconomic status to 
have any impact on risk of infection; it was only associ-
ated with the risk of hospital admission for COVID-19. 
However, reports in other countries have shown that 
the most disadvantaged and vulnerable people are at 
increased risk for contracting COVID-19, because of 
possible factors such as poorer baseline health status, 
closer social contacts and lack of access to healthcare 
[27,28]. In our scenario, the universal healthcare sys-
tem (RDL 7/2018) [29] in Spain might have played a role 
in our results, as access to healthcare would not have 
been limited regardless of socioeconomic status.
Table 3
Adjusted hazard ratios and 95% confidence intervals for hospitalisation for COVID-19, by comorbidities and individual 
socioeconomic status, Catalonia, Spain, 30 April 2020
Characteristics Adjusted hazard ratio Lower 0.95 CI Upper 0.95 CI p value
Hypertension 1.40 0.82 2.38 0.20
Diabetes 1.04 0.54 1.97 0.90
Heart failure 0.83 0.33 2.09 0.70
COPD 1.17 0.57 2.40 0.60
Chronic renal disease 1.70 0.89 3.25 0.10
Asthma 1.42 0.69 2.90 0.30
Dementia 1.17 0.28 4.90 0.80
Liver cirrhosis 2.01 0.27 14.72 0.50
Stroke 1.28 0.57 2.88 0.50
Coronary artery disease 0.89 0.34 2.33 0.80
Cancer 1.44 0.80 2.60 0.20
Current smoker 0.58 0.29 1.16 0.10
Former smoker 1.23 0.68 2.19 0.48
IS level < 18,000 € 1.91 0.46 7.83 0.37
IS level 18,001–100,000 € 1.08 0.25 4.76 0.9
IS level  > 100,000 € 0 0 – 0.99
CQ/HCQ exposure 1.46 0.91 2.34 0.10
CI: confidence interval; COPD: chronic obstructive pulmonary disease; COVID-19: coronavirus disease; CQ/HCQ: chloroquine/
hydroxychloroquine; IS level: individual socioeconomical level.
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Limitations of the available data and study approach 
must also be acknowledged. We did not explore con-
current medications; some of the treatments used for 
autoimmune diseases may also influence both suscep-
tibility to infection and severity of disease, and this 
may have led to residual confounding. We did not have 
information regarding the daily doses of CQ/HCQ per 
patient, and the dose could also influence the results. 
However, as this study analyses the effect of pre-expo-
sure, we consider that chronic administration of higher 
doses than are commonly prescribed would not be 
feasible in general practice because of the expected 
side effects. As medication data were obtained from 
the pharmacy invoicing database, we could not assure 
treatment compliance. However, as these are mainly 
chronic treatments, we inferred compliance by select-
ing those individuals with chronic dispensation for 6 
months before starting follow-up. The risk of SARS-
CoV-2 infection is also influenced by environmental 
characteristics, which have not been controlled. To 
overcome this, primary care service area was also a 
matching parameter for the control cohort. Regarding 
hospitalisation, episodes of inpatient and outpatient 
care carried out in private hospitals were not available 
for this analysis. However, during the COVID-19 epi-
demic all private hospitals reported COVID-19 cases to 
the public healthcare system, so we can be confident 
that all cases were identified. Finally, around 80% of 
the study population were female, probably because 
current prescriptions for CQ/HCQ are for autoimmune 
diseases (such as rheumatoid arthritis), which are 
known to be more common in women. This is a major 
limitation with respect to generalisation of the results 
to a male population.
Clinical trials continue to be the gold standard to gen-
erate evidence regarding drug efficacy, but they are 
difficult to implement in rapidly evolving, emergency 
conditions, because of demanding implementation 
requirements. However, this analysis of the impact of 
long-term 4-aminoquinolines therapy on the incidence 
of COVID-19 is intended to serve as supportive infor-
mation to guide clinical practice while more robust evi-
dence is generated.
Conclusions
Patients chronically exposed to 4-aminoquinolines 
(CQ/HCQ) did not differ from non-exposed controls 
with regard to risk of infection by SARS-CoV-2. Although 
patients receiving these drugs were hospitalised more 
often, the risk may not be attributed to the drug, but to 
a higher proportion of comorbidities.
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